Health Canada Accepts to Review Theratechnologies' New Drug Submission for EGRIFTAŽ
MONTREAL, CANADA-(Aug. 16, 2011) - Theratechnologies Inc. (TSX: TH) (NASDAQ: THER)
today announced that the Therapeutic Products Directorate of Health Canada has accepted to review its New Drug Submission (NDS) for EGRIFTAŽ
(tesamorelin for injection) filed in late June.
"We are pleased that Health Canada has completed the screening of our NDS for EGRIFTAŽ and has accepted to move forward with the
technical review," stated Mr. John-Michel T. Huss, President and Chief Executive Officer of Theratechnologies. "We look forward
to working with Health Canada throughout the review process," added Mr. Huss.
EGRIFTAŽ, or tesamorelin, is an analogue of the growth hormone-releasing factor (GRF) proposed for the treatment of excess abdominal
fat in HIV-infected patients with lipodystrophy. Currently, there is no approved treatment for lipodystrophy in HIV patients available
in Canada.
The NDS is based on the positive results from two Phase 3 clinical trials, which enrolled more than 800 patients, and follows
a marketing approval for EGRIFTAŽ by the U.S. Food and Drug Administration received in November 2010. Additional applications for
tesamorelin for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy are currently under review
with regulatory agencies in Europe and Israel.
About EGRIFTA ®
EGRIFTA ® , a once-daily injection, is a novel, stabilized analogue of GRF. GRF is a hypothalamic peptide that acts on the pituitary
cells in the brain to stimulate the synthesis and pulsatile release of endogenous growth hormone (GH). GH has been shown to play an
important role in regulating lipid metabolism and body composition (e.g., increasing muscle mass and reducing fat) 1 . For more
information about EGRIFTA ® , including its U.S. Food and Drug Administration approved indications, limitations of use and
complete risk profile, please consult the full U.S. Prescribing Information available
at www.egrifta.com/Pdfs/Prescribing_Information.pdf . EGRIFTA ® has
not been approved in Canada.
About HIV-Associated Lipodystrophy
Several factors, including a patient's antiretroviral drug regimen and the HIV virus itself, are thought to contribute to HIV-associated
lipodystrophy, which is characterized by body composition changes. The changes in body composition may include accumulation of excess
abdominal fat accumulation, which is known as abdominal lipohypertrophy.
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THER) is a specialty pharmaceutical company that discovers and develops innovative therapeutic
peptide products, with an emphasis on growth-hormone releasing factor peptides. Its first product, EGRIFTA ® (tesamorelin for
injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA ® is the only
approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. EGRIFTA ® has not
been approved in Canada.
EGRIFTA ® is currently marketed in the United States by EMD Serono pursuant to a collaboration and licensing agreement executed
in October 2008. In addition, Theratechnologies has signed distribution and licensing agreements with a subsidiary of Sanofi granting
them the exclusive commercialization rights for EGRIFTA ® for the treatment of excess abdominal fat in HIV-infected patients with
lipodystrophy in Latin America, Africa and the Middle East and with Ferrer Internacional S.A. granting them the exclusive
commercialization rights for EGRIFTA ® for the treatment of excess abdominal fat in HIV-infected patients with
lipodystrophy in Europe, Russia, South Korea, Taiwan, Thailand and certain central Asian countries.
Theratechnologies is also looking to develop tesamorelin for the treatment of patients suffering from muscle wasting associated with
Chronic Obstructive Pulmonary Disease (COPD). Tesamorelin has been shown to increase muscle mass, which makes it a potential
treatment for muscle wasting. The COPD clinical program is expected to begin in September 2011.
Additional Information about Theratechnologies
Further information about Theratechnologies is available on the Company's website
at http://www.theratech.com/ . Additional information, including the Annual
Information Form and the Annual Report, is also available on SEDAR at http://www.sedar.com/ and on
the Securities and Exchange Commission's website at http://www.sec.gov/ .
Forward-Looking Information
This press release contains certain statements that are considered "forward-looking information" within the meaning of applicable
securities legislation, which statements may contain such words as "may", "would", "could", "will", "intend", "plan",
"anticipate", "believe", "estimate", "expect" and similar expressions. This forward-looking information
includes, but is not limited to, information regarding the potential approval of EGRIFTA ® for the
treatment of excess abdominal fat in adult HIV-infected patients with lipodystrophy in Canada and in other jurisdictions.
Forward-looking information is based upon a number of assumptions and is subject to a number of risks and uncertainties, many
of which are beyond Theratechnologies' control that could cause actual results to differ materially from those that are disclosed
in or implied by such forward-looking information. These assumptions include, but are not limited to, that Health Canada and
other regulatory agencies in other jurisdictions will approve EGRIFTA ® for the treatment of excess abdominal fat in
adult HIV-infected patients with lipodystrophy and that no additional clinical trials will be required by Health
Canada and other regulatory agencies in other jurisdictions in order to approve EGRIFTA ® . These risks and
uncertainties include, but are not limited to, the risk that Health Canada and other regulatory agencies in
other jurisdictions do not approve EGRIFTA ® for the treatment of excess abdominal fat in adult
HIV-infected patients with lipodystrophy or that Health Canada or other regulatory agencies in
other jurisdictions require additional clinical studies prior to make any decision regarding
the approval or non-approval of EGRIFTA ® .
Theratechnologies refers potential investors to the "Risks and Uncertainties" section of its Annual Information
Form (AIF) dated February 22, 2011. The AIF is available at http://www.sedar.com/ and
at http://www.sec.gov/ under Theratechnologies' public filings. The reader is cautioned
to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements.
Forward-looking information reflects current expectations regarding future events and speaks only as of the date of
this press release and represents Theratechnologies' expectations as of that date.
Theratechnologies undertakes no obligation to update or revise the information contained in this press release, whether as a result
of new information, future events or circumstances or otherwise, except as may be required by applicable law.
1 Grunfeld C et al. J Acquir Immune Defic Syndr; 45:286-297 (2007). Lo J et al. JAMA, 300: 509518 (2008).
Source: Theratechnologies Inc.
http://www.theratech.com/en/investor-relations/news.php?id=416
"Reproduced with permission - Theratechnologies "
Theratechnologies
|
